Moderna (MRNA) Other Non Operating Income (2018 - 2026)

Moderna has reported Other Non Operating Income for 9 years, with the latest figure at -$19.0 million in Q2 2026.

• Other Non Operating Income for Q2 2026 came in at -$19.0 million, down 337.5% year-over-year; the trailing twelve-month figure through Jun 2026 was -$49.0 million (down 32.43% YoY), and the FY2025 annual result was -$8.0 million, up 90.8% from the prior year.
• Other Non Operating Income declined to -$19.0 million in Q2 2026, from -$18.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $14.0 million in Q2 2023 and troughed at -$51.0 million in Q3 2023.
• A 5-year average of -$17.7 million and a median of -$13.0 million in 2022 frame the typical range for Other Non Operating Income.
• The largest YoY upside for Other Non Operating Income was 207.69% in 2023 against a maximum downside of 628.57% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at -$12.0 million in 2022, then tumbled by 225.0% to -$39.0 million in 2023, then increased by 25.64% to -$29.0 million in 2024, then jumped by 58.62% to -$12.0 million in 2025, then sank by 58.33% to -$19.0 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were -$19.0 million in Q2 2026, -$18.0 million in Q1 2026, and -$12.0 million in Q4 2025.